About: A Targeted Vaccine against COVID-19: S1-Fc Vaccine Targeting the Antigen-Presenting Cell Compartment Elicits Protection against SARS-CoV-2 Infection

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A Targeted Vaccine against COVID-19: S1-Fc Vaccine Targeting the Antigen-Presenting Cell Compartment Elicits Protection against SARS-CoV-2 Infection Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	A Targeted Vaccine against COVID-19: S1-Fc Vaccine Targeting the Antigen-Presenting Cell Compartment Elicits Protection against SARS-CoV-2 Infection
Creator	Herrmann, Andreas Paessler, Slobodan Maruyama, Junki Ji, Henry Zhang, Yanliang Adamus, Tomasz Fu, Yanwen Guo, Whenzong Hoo, William Johnson, Sachi Kerwin, Lisa Kwon, Sunkuk Lahtz, Christoph Ledesma, Arthur Praessler, Slobodan Yei, Elena Yei, Soonpin Yue, Chanyu Zhou, Heyue Zhou, Yiran Zhuang, Yingcong
source	BioRxiv
abstract	Vaccination efficacy is enhanced by targeting the antigen-presenting cell compartment. Here, we show that S1-Fc antigen delivery targeting the FcγR+ antigen-presenting cell compartment elicits anti-SARS-CoV-2 S1-antigen specific IgG production in vivo exerting biologically functional and protective activity against live virus infection, assessed in a stringent experimental virus challenge assay in vitro. The S1-domain of the SARS-CoV-2 spike protein was genetically fused to a human immunoglobulin Fc moiety, which contributes to mediate S1-Fc cellular internalization by FcγR+ antigen-presenting cells. Immediately upon administration intramuscularly, our novel vaccine candidate recombinant rS1-Fc homes to lymph nodes in vivo where FcγR+ antigen-presenting cells reside. Seroconversion is achieved as early as day 7, mounting considerably increased levels of anti-S1 IgGs in vivo. Interestingly, immunization at elevated doses with non-expiring S1-Fc encoding dsDNA favors the education of a desired antigen-specific adaptive T cell response. However, low-dose immunization, safeguarding patient safety, using recombinant rS1-Fc, elicits a considerably elevated protection amplitude against live SARS-CoV-2 infection. Our promising findings on rS1-Fc protein immunization prompted us to further develop an affordable and safe product for delivery to our communities in need for COVID-19 vaccinations.
has issue date	2020-06-30(xsd:dateTime)
bibo:doi	10.1101/2020.06.29.178616
has license	biorxiv
sha1sum (hex)	3cb4717f48721a72a310431d008821b717029329
schema:url	https://doi.org/10.1101/2020.06.29.178616
resource representing a document's title	A Targeted Vaccine against COVID-19: S1-Fc Vaccine Targeting the Antigen-Presenting Cell Compartment Elicits Protection against SARS-CoV-2 Infection
schema:publication	bioRxiv
resource representing a document's body	covid:3cb4717f48721a72a310431d008821b717029329#body_text
is schema:about of	named entity 'genetically' named entity 'mediate' named entity 'virus' named entity 'Compartment' named entity 'FUNCTIONAL' named entity 'EARLY' named entity 'ACTIVITY' named entity 'RESIDE' named entity 'HERE' named entity 'T CELL RESPONSE' named entity 'PROTEIN ' named entity 'administration' named entity 'antigen-presenting cells' named entity 'response' named entity 'stringent' named entity 'mounting' named entity 'assay' named entity 'vivo' named entity 'targeting' named entity 'antigen-presenting cells' named entity 'antigen-presenting cell' named entity 'SARS-CoV-2' named entity 'antigen-presenting cell' named entity 'dsDNA' named entity 'Vaccination' named entity 'Vaccine' named entity 'SARS-CoV-2' named entity 'protein' named entity 'macrophages' named entity 'ATCC' named entity 'immunization' named entity 'targeted immunization' named entity 'recombinant' named entity 'CD8 +' named entity 'serum' named entity 'immunization' named entity 'immunization' named entity 'SARS-CoV-2' named entity 'anergic' named entity 'SARS-CoV-2 virus' named entity 'inflammatory responses' named entity 'anaesthetized' named entity 'confocal microscopy' named entity 'seroconversion' named entity 'cell nucleus' named entity 'Invitrogen' named entity 'SARS-CoV-2' named entity 'cell cytoplasm' named entity 'gel electrophoresis' named entity 'immunization' named entity 'immune responses' named entity 'lymphatics' named entity 'biceps femoris' named entity 'immunization' named entity 'prophylactic' named entity 'flow cytometry' named entity 'protein' named entity 'immunoglobulin' named entity 'antigen presentation' named entity 'fibroblasts' named entity 'immunizing' named entity 'serum' named entity 'CD11c' named entity 'recombinant'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software